Blandine Lacroix is Corporate Vice President, BioPharm & Strategy since September 1, 2020. In her role, she is responsible for managing the U.S. Biopharmaceuticals commercial team that specializes in treatments for people with hemophilia and other rare bleeding disorders and growth hormone-related disorders along with leading the U.S. organization’s enterprise strategy.
Prior to that, Ms. Lacroix led the Obesity business at Novo Nordisk Inc. since October 2017. During that time, she was responsible for driving strategies transforming how the world sees, prevents and treats the disease.
Ms. Lacroix is a proven global commercial leader who brings over 20 years of experience in marketing and commercial leadership within the pharmaceutical industry. She joined Novo Nordisk in 2002 in the company’s Australia affiliate. Since that time, she has progressed through roles of escalating responsibility leading global marketing teams, at the company’s headquarters in Denmark and within the US affiliate, across both diabetes and obesity therapeutic areas. Ms. Lacroix led the establishment of the company’s US obesity business as Vice President, Obesity Marketing, from 2013 to 2017.
Before joining Novo Nordisk, Ms. Lacroix managed teams and business opportunities for several international companies across diverse industries such as technology, health, manufacturing, and education.
Ms. Lacroix was awarded the Princeton YMCA Centennial Award for Healthy Living, which recognizes leaders in environmental wellbeing and sustainability, in 2017.
Ms. Lacroix studied business with a major in Finance and Accounting
as an undergraduate at the MBA Institute in Paris, France, and has a
Master of International Business from the University of South